stockrow
Friday 6 November 2026
Export GOSS’s income statement to Excel — free account
Gossamer Bio, Inc.
GOSS Healthcare Biotechnology
Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024.
- Revenue
- −19.6%
- EPS
- +129.4%
- Free cash flow
- +16.3%
- Total debt
- −81.7%
Quarter to June 2026, against a year earlier
9.75
0.33
+3.50%
Follow GOSS
Alert me
Gossamer Bio, Inc. (GOSS) P/E ratio
Gossamer Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| CLNN Clene Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 7.4× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)